Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2009

Open Access 01-12-2009 | Research article

Expression and prognostic significance of THBS1, Cyr61 and CTGF in esophageal squamous cell carcinoma

Authors: Zhu-Qing Zhou, Wei-Hua Cao, Jian-Jun Xie, Jing Lin, Zhong-Ying Shen, Qing-Ying Zhang, Jin-Hui Shen, Li-Yan Xu, En-Min Li

Published in: BMC Cancer | Issue 1/2009

Login to get access

Abstract

Background

Thrombospondin1 (THBS1), cystene-rich protein 61 (Cyr61) and connective tissue growth factor (CTGF) are all involved in the transforming growth factor-beta (TGF-β) signal pathway, which plays an important role in the tumorigenesis. The purpose of this study is to explore the expression and prognostic significance of these proteins in esophageal squamous cell carcinoma (ESCC).

Methods

We used immunohistochemistry and western blotting to examine the expression status of THBS1, Cyr61 and CTGF in ESCC. Correlations of THBS1, Cyr61 and CTGF over-expressions with various clinicopathologic factors were also determined by using the Chi-square test or Fisher's exact probability test. Survival analysis was assessed by the Kaplan-Meier analysis and the log-rank test. Relative risk was evaluated by the multivariate Cox proportional hazards model.

Results

THBS1, Cyr61 and CTGF were all over-expressed in ESCC. THBS1 over-expression was significantly associated with TNM stage (P = 0.029) and regional lymph node involvement (P = 0.026). Kaplan-Meier survival analysis showed that over-expression of THBS1, Cyr61 or CTGF was related to poor survival of ESCC patients (P = 0.042, P = 0.020, P = 0.018, respectively). Multivariate Cox analysis demonstrated that Cyr61 and CTGF were independent factors in prognosis of ESCC.

Conclusion

Cyr61, CTGF and THBS1 were all over-expressed in ESCC and might be new molecular markers to predict the prognosis of ESCC patients.
Appendix
Available only for authorised users
Literature
1.
Lam KY, Law S, Tung PH, Wong J: Esophageal small cell carcinomas: clinicopathologic parameters, p53 overexpression, proliferation marker, and their impact on pathogenesis. Arch Pathol Lab Med. 2000, 124: 228-233.PubMed
2.
Enzinger PC, Mayer RJ: Esophageal cancer. N Engl J Med. 2003, 349: 2241-2252. 10.1056/NEJMra035010.CrossRefPubMed
3.
Pardali K, Moustakas A: Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer. Biochim Biophys Acta. 2007, 1775: 21-62.PubMed
4.
Benckert C, Jonas S, Cramer T, Von Marschall Z, Schäfer G, Peters M, Wagner K, Radke C, Wiedenmann B, Neuhaus P, Höcker M, Rosewicz S: Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells. Cancer Res. 2003, 63: 1083-1092.PubMed
5.
Muraoka-Cook RS, Dumont N, Arteaga CL: Dual role of transforming growth factor beta in mammary tumorigenesis and metastatic progression. Clin Cancer Res. 2005, 11: 937s-943s.PubMed
6.
Elliott RL, Blobe GC: Role of transforming growth factor Beta in human cancer. J Clin Oncol. 2005, 23: 2078-2093. 10.1200/JCO.2005.02.047.CrossRefPubMed
7.
Crawford SE, Stellmach V, Murphy-Ullrich JE, Ribeiro SM, Lawler J, Hynes RO, Boivin GP, Bouck N: Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell. 1998, 93: 1159-1170. 10.1016/S0092-8674(00)81460-9.CrossRefPubMed
8.
Annes JP, Munger JS, Rifkin DB: Making sense of latent TGF beta activation. J Cell Sci. 2003, 116: 217-224. 10.1242/jcs.00229.CrossRefPubMed
9.
Bartholin L, Wessner LL, Chirgwin JM, Guise TA: The human Cyr61 gene is a transcriptional target of transforming growth factor beta in cancer cells. Cancer Letters. 2007, 246: 230-236. 10.1016/j.canlet.2006.02.019.CrossRefPubMed
10.
Holmes A, Abraham DJ, Sa S, Shiwen X, Black CM, Leask A: CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling. J Biol Chem. 2001, 276: 10594-10601. 10.1074/jbc.M010149200.CrossRefPubMed
11.
Bleau AM, Planque N, Perbal B: CCN proteins and cancer: two to tango. Front Biosci. 2005, 10: 998-1009. 10.2741/1594.CrossRefPubMed
12.
Sargiannidou I, Zhou J, Tuszynski GP: The role of thrombospondin-1 in tumor progression. Exp Biol Med. 2001, 226: 726-733.
13.
Oshiba G, Kijima H, Himeno S, Kenmochi T, Kise Y, Tanaka H, Nishi T, Chino O, Shimada H, Machimura T, Tsuchida T, Nakamura M, Ueyama Y, Tanaka M, Tajima T, Makuuchi H: Stromal thrombospondin-1 expression is correlated with progression of esophageal squamous cell carcinomas. Anticancer Res. 1999, 19: 4375-4378.PubMed
14.
Di Martino E, Wild CP, Rotimi O, Darnton JS, Olliver RJ, Hardie LJ: IGFBP-3 and IGFBP-10 (CYR61) up-regulation during the development of Barrett's oesophagus and associated oesophageal adenocarcinoma: potential biomarkers of disease risk. Biomarkers. 2006, 11: 547-561. 10.1080/13547500600896791.CrossRefPubMed
15.
Deng YZ, Chen PP, Wang Y, Yin D, Koeffler HP, Li B, Tong XJ, Xie D: Connective Tissue Growth Factor Is Overexpressed in Esophageal Squamous Cell Carcinoma and Promotes Tumorigenicity through beta-Catenin-T-cell Factor/Lef Signaling. J Biol Chem. 2007, 282: 36571-36581. 10.1074/jbc.M704141200.CrossRefPubMed
16.
Koliopanos A, Friess H, di Mola FF, Tang WH, Kubulus D, Brigstock D, Zimmermann A, Büchler MW: Connective Tissue Growth Factor Gene Expression Alters Tumor Progression in Esophageal Cancer. World J Surg. 2002, 26: 420-427. 10.1007/s00268-001-0242-x.CrossRefPubMed
17.
Zhang FR, Tao LH, Shen ZY, Lv Z, Xu LY, Li EM: Fascin expression in human embryonic, fetal, and normal adult tissue. J Histochem Cytochem. 2008, 56: 193-199. 10.1369/jhc.7A7353.2007.CrossRefPubMedPubMedCentral
18.
Kuwano H, Kato H, Miyazaki T, Fukuchi M, Masuda N, Nakajima M, Fukai Y, Sohda M, Kimura H, Faried A: Genetic alterations in esophageal cancer. Surg Today. 2005, 35: 7-18. 10.1007/s00595-004-2885-3.CrossRefPubMed
19.
Lebman DA, Edmiston JS, Chung TD, Snyder SR: Heterogeneity in the transforming growth factor beta response of esophageal cancer cells. Int J Oncol. 2002, 20: 1241-1246.PubMed
20.
Miller AV, Alvarez SE, Spiegel S, Lebman DA: Sphingosine kinases and sphingosine-1-phosphate are critical for transforming growth factor beta-induced extracellular signal-regulated kinase 1 and 2 activation and promotion of migration and invasion of esophageal cancer cells. Mol Cell Bio. 2008, 28: 4142-4151. 10.1128/MCB.01465-07.CrossRef
21.
Rees JR, Onwuegbusi BA, Save VE, Alderson D, Fitzgerald RC: In vivo and in vitro evidence for transforming growth factor-beta1-mediated epithelial to mesenchymal transition in esophageal adenocarcinoma. Cancer Res. 2006, 66: 9583-9590. 10.1158/0008-5472.CAN-06-1842.CrossRefPubMed
22.
Planque N, Perbal B: A structural approach to the role of CCN (CYR61/CTGF/NOV) proteins in tumourigenesis. Cancer Cell Int. 2003, 3: 15-29. 10.1186/1475-2867-3-15.CrossRefPubMedPubMedCentral
23.
Tsai MS, Bogart DF, Li P, Mehmi I, Lupu R: Expression and regulation of Cyr61 in human breast cancer cell lines. Oncogene. 2002, 21: 964-973. 10.1038/sj.onc.1205131.CrossRefPubMed
24.
Tong X, Xie D, O'Kelly J, Miller CW, Muller-Tidow C, Koeffler HP: Cyr61, a member of CCN family, is a tumor suppressor in non-small cell lung cancer. J Biol Chem. 2001, 276: 47709-47714. 10.1074/jbc.M107878200.CrossRefPubMed
25.
Xie D, Yin D, Tong X, O'Kelly J, Mori A, Miller C, Black K, Gui D, Said JW, Koeffler HP: Cyr61 is overexpressed in gliomas and involved in integrin-linked kinase-mediated Akt and beta-catenin-TCF/Lef signaling pathways. Cancer Res. 2004, 64: 1987-1996. 10.1158/0008-5472.CAN-03-0666.CrossRefPubMed
26.
Chen PP, Li WJ, Wang Y, Zhao S, Li DY, Feng LY, Shi XL, Koeffler HP, Tong XJ, Xie D: Expression of Cyr61, CTGF, and WISP-1 correlates with clinical features of lung cancer. PLoS ONE. 2007, 2: e534-10.1371/journal.pone.0000534.CrossRefPubMedPubMedCentral
27.
Watari H, Xiong Y, Hassan MK, Sakuragi N: Cyr61, a member of ccn (connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed) family, predicts survival of patients with endometrial cancer of endometrioid subtype. Gynecol Oncol. 2009, 112: 229-234. 10.1016/j.ygyno.2008.09.039.CrossRefPubMed
28.
Rojas A, Meherem S, Kim YH, Washington MK, Willis JE, Markowitz SD, Grady WM: The aberrant methylation of TSP1 suppresses TGF-beta1 activation in colorectal cancer. Int J Cancer. 2008, 123: 14-21. 10.1002/ijc.23608.CrossRefPubMedPubMedCentral
29.
Astolfi A, De Giovanni C, Landuzzi L, Nicoletti G, Ricci C, Croci S, Scopece L, Nanni P, Lollini PL: entification of new genes related to the myogenic differentiation arrest of human rhabdomyosarcoma cells. Gene. 2001, 274: 139-149. 10.1016/S0378-1119(01)00619-9.CrossRefPubMed
30.
Grossfeld GD, Ginsberg DA, Stein JP, Bochner BH, Esrig D, Groshen S, Dunn M, Nichols PW, Taylor CR, Skinner DG, Cote RJ: Thrombospondin-1 expression in bladder cancer: Association with p53 alterations, tumor angiogenesis, and tumor progression. J Natl Cancer Inst. 1997, 89: 219-227. 10.1093/jnci/89.3.219.CrossRefPubMed
31.
Ohtani Y, Kijima H, Dowaki S, Kashiwagi H, Tobita K, Tsukui M, Tanaka Y, Tsuchida T, Tokunaga T, Yamazaki H, Nakamura M, Ueyama Y, Tanaka M, Tajima T, Makuuchi H: Stromal expression of thrombospondin-1 is correlated with growth and metastasis of human gallbladder carcinoma. Int J Oncol. 1999, 15: 453-457.PubMed
32.
Miyamoto N, Yamamoto H, Taniguchi H, Miyamoto C, Oki M, Adachi Y, Imai K, Shinomura Y: Differential expression of angiogenesis-related genes in human gastric cancers with and those without high-frequency microsatellite instability. Cancer Lett. 2007, 254: 42-53. 10.1016/j.canlet.2007.02.004.CrossRefPubMed
33.
Guerrero D, Guarch R, Ojer A, Casas JM, Ropero S, Mancha A, Pesce C, Lloveras B, Garcia-Bragado F, Puras A: Hypermethylation of the thrombospondin-1 gene is associated with poor prognosis in penile squamous cell carcinoma. BJU Int. 2008, 102: 747-755. 10.1111/j.1464-410X.2008.07603.x.CrossRefPubMed
34.
Metadata
Title
Expression and prognostic significance of THBS1, Cyr61 and CTGF in esophageal squamous cell carcinoma
Authors
Zhu-Qing Zhou
Wei-Hua Cao
Jian-Jun Xie
Jing Lin
Zhong-Ying Shen
Qing-Ying Zhang
Jin-Hui Shen
Li-Yan Xu
En-Min Li
Publication date
01-12-2009
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2009
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-9-291

Other articles of this Issue 1/2009

BMC Cancer 1/2009 Go to the issue

Research article

Risk factors for lower limb lymphedema after lymph node dissection in patients with ovarian and uterine carcinoma

Research article

Knowledge, attitudes and practice of breast cancer screening among female health workers in a Nigerian urban city

Research article

Polymorphisms in the xenobiotic transporter Multidrug Resistance 1 (MDR1) and interaction with meat intake in relation to risk of colorectal cancer in a Danish prospective case-cohort study

Research article

The interaction of HAb18G/CD147 with integrin α6β1 and its implications for the invasion potential of human hepatoma cells

Technical advance

An informatics supported web-based data annotation and query tool to expedite translational research for head and neck malignancies

Research article

Colorectal carcinomas in MUTYH-associated polyposis display histopathological similarities to microsatellite unstable carcinomas
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits